Amiodarone as paradigm for developing new drugs for atrial fibrillation

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 4, 2008, Pages 300-305

  Singh, Bramah N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Amiodarone; Amiodarone congeners; Atrial fibrillation; Dronedarone

Indexed keywords

1 (2 BUTYL 3 BENZOFURANYL) 1 [5 [2 (DIETHYLAMINO)ETHOXY] 2 THIENYL]METHANONE; AMIODARONE; ANTIARRHYTHMIC AGENT; AT 2042; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIVARONE; DOFETILIDE; DRONEDARONE; IRBESARTAN; KBI 30015; PLACEBO; PROPAFENONE; PROPRANOLOL; RANOLAZINE; SOTALOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANGINA PECTORIS; ATAXIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; CORNEA DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG USE; ECCHYMOSIS; EPIDIDYMIS; GYNECOMASTIA; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; KIDNEY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; MASTALGIA; MEMORY DISORDER; MYOPATHY; NAUSEA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PIGMENTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA DEGENERATION; REVIEW; SIDE EFFECT; SINUS ARREST; SINUS RHYTHM; SKIN; THROMBOCYTOPENIA; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VOMITING; CHEMICAL STRUCTURE; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; HEART MUSCLE CONDUCTION SYSTEM; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEART CONDUCTION SYSTEM; HUMANS; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 58149354536     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818914b6     Document Type: Review

References (39)

1. Singh BN. Amiodarone: A multifaceted anti-arrhythmic drug. Curr Cardiol Rep. 2006;8:349-355.
2. Fitzgerald JD. Class III Antiarrhythmic agents: serendipity or drug design? Dialogues in Cardiovascular Medicine 2004;9:243-252.
3. Singh BN. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol. 1996;78:41-53.
4. Singh BN. Overview of trends in the control of cardiac arrhythmia: Past and future. Am J Cardiol. 1999;84:3R-10R.
5. Charlier R, Deltour G, Baudine A, et al. Pharmacology of amiodarone: an antianginal drug with a new biological profile. Arzneimittelforschung 1968;18:1408-1430.
6. Singh BN, Vaughan Williams EM. The effect of amiodarone: a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970;39:657-667.
7. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic actions? Effects on trial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle, of MJ and AH 3474. Br J Pharmacol. 1970;39:675-687.
8. Singh BN. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol. 1996:78(Suppl 4A):17-27.
9. Singh BN. Antiarrhythmic actions of amiodarone: a profile of an paradoxical agent. Am J Cardiol. 1996;81:7841-7853.
10. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Eng J Med. 1999:341:871.
11. Dorian PD, Schwartz, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002:346:884-890.
12. Middlekauff HR, Wiener I, Saxon LA, et al. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med. 1992; 116:1017.
13. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
14. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atria Fibrillation Investigators. N Engl J Med. 2000;342:913-920.
15. Nattel S. Khairy P, Roy D, et al. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs. 2002;62: 2377-2397.
16. Singh BN. Atria fibrillation: Epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Therapeut. 2003;8:13-26.
17. Deedwania PK, Singh BN, Ellenbogan K, et al. Spontaneous conversion an maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of AntiarrhythmicTherapy (CHF-STAT). Circulation. 1998;23:2574-2579.
18. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med. 1995;333:77-82.
19. Nattel S,Singh BN. Evolution, mechanisms, and classifications of antiarrhy-thmic drugs: Focus on class III actions. Am J Cardiol. 1999;84:11R-19R.
20. Singh SN, Tang CX, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation. J Am Coll Cardiol. 2006;48:721-730.
21. Singh BN: A symposium: Approaches to controlling cardiac arrhythmias: focus on Amiodarone, the last 15 years. Am J Cardiol. 1999;84:1R-173R.
22. Madrid AH, Bueno AH, Rebollo JM, et al. Use of iebsartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study in patients with long-lasting persistent atrial fibrillation. Circulation. 2002;106:331-336.
23. Nagele H, Bohlmann M, ECK U, et al. Combination therapy with carvedilol and amiodarone and patients with severe hear failure. Eur J Heat Fail. 2000;2:7179.
24. Fedida D, Orth PMR, Chen JYC, et al. The mechanism of atrial antiarrhythmic actions of RSD1235. J Cardiovasc Electrophysiol. 2005; 16:1227-1238.
25. Roy D, Pratt CM, Torp-Pedersen C, et al; for the Atria Arrhythjmia Conversion Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo trial. Circulation. 2008;117:1518-1525.
26. Djandjighian L, Planchenault, J, Finance O, et al. Hemodynamic and anti-adrenergic effects of dronedarone and amiodarone, in animals with a in animals with a healed myocardial infarction. J Cardiocardivas Pharmaco. 2000;46:376-383.
27. Gautier P, Guillaremare E, Djandjighian L, et al. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR1149744C. Electrophysiological anti-adrenergic and anti-angiotensin II effects. J Cardiovascul Pharmaco. 2004;244-257.
28. Carlsson B, Singh BN, Temciuc M, et al. Synthesis and preliminary characterization of a novel compound (KBI30015) with an improved toxicity profile compared with amiodarone. J Medicin Chem. 2002;45:623-630.
29. Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative in the rabbit heart. Comparison with amiodarone. Circulation. 1999;100: 2276-2283.
30. Holnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121:529-537.
31. Hohnloser S, Singh BN. Proarrhythmia with class III antiarrhythmic drugs. Definition, electrophysiologic mechanism, incidence, predisposing factors, and clinical implications. J Electrophysiol. 1995;6:920-936.
32. Singh BN. Antiarrhythmic drugs. In: Pharmacologic and Interventional Therapies. Electrophysiologiccal Disorders of the Heart. Sanjeev S, Camm AJ (ads). Philadelphia: Elsevier Churchill Livingstone; 2005: 705-729.
33. Sicouri S, Moro S, Elizari MV. d-sotalol indices marked action potential prolongation and early afterdepolarizations in M but not Epicardial or endocardial cells of the canine ventricle. J Cardiovasc Pharmacocol Therapeut. 1997;2:27-38.
34. Antzelevitz C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel anti-anginal agent with anti-arrhythmic properties. Circulation. 204;110:904-910.
35. Touboul P, Brugada J, Capucc A, et al. Dronedarone for the prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487.
36. Singh BN, Connolly SJ, Crijns HJGM et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357: 987-999.
37. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358: 78-87.
38. Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: A placebo-controlled, parallel- arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospi-talization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol. 2008;19:69-73.
39. Holnloser SH. Effects of dronedarone on cardiovascular outcomes in high risk patients with atria fibrillation or atria flutter- results of the athena trial. Heart Rhythm 29th Annual Scientic Sessions, May 14-27, 2008. San Francisco.